Felix Health Launches Generic Semaglutide Waitlist in Canada

First Commercial Waitlist Opens

The Toronto-based telehealth company announced its generic semaglutide waitlist on March 10, 2026, allowing Canadians to register for notifications when generic versions become available. Felix indicated that generic formulations will contain the same active ingredient as branded Ozempic and Wegovy medications.

The waitlist launch represents the first patient-facing preparation by a Canadian healthcare provider for the anticipated generic semaglutide market entry. Felix operates telehealth services across all provinces and territories in Canada.

Health Canada Review Status

Health Canada continues reviewing nine generic semaglutide applications submitted by various pharmaceutical companies. The regulatory review process began after Novo Nordisk's patent exclusivity expired on January 4, 2026.

Companies with applications under review include:

• Sandoz Canada
• Apotex Inc.
• Teva Canada Limited
• Taro Pharmaceuticals Canada
• Aspen Pharmacare Canada
• Vimy Pharma Ltd.

Canadians can track the progress of these applications through Health Canada's generic semaglutide tracker system.

Expected Market Impact

Industry analysts project generic semaglutide could launch at prices 65-70% below current brand prices. Current pricing for brand-name semaglutide medications ranges from CAD $200-400 monthly depending on strength and pharmacy location.

The generic market entry is expected to significantly impact both private insurance plans and out-of-pocket costs for Canadian patients. Many employers are already adjusting their drug benefit programs in anticipation of lower-cost alternatives.

Provincial Considerations

Different provinces may have varying timelines for generic semaglutide coverage under public drug plans. British Columbia's new national pharmacare program, which launched in March 2026, has indicated interest in including generic versions when available.

Private insurance providers are also preparing coverage policies for generic alternatives. Patients can check potential coverage through various insurance coverage checker tools.

Timeline Expectations

While Felix's waitlist suggests preparation for imminent availability, Health Canada has not provided specific approval timelines for the nine applications under review. Generic manufacturers have indicated potential launch dates ranging from mid-2026 to early 2027, pending regulatory approval.

The Mounjaro patent, held by Eli Lilly, remains in effect until 2031, meaning tirzepatide will not face generic competition in the near term.

Market Preparation

Felix's waitlist launch follows broader industry preparation for generic competition. Novo Nordisk has announced plans to launch renamed versions of its semaglutide products at reduced prices to compete with generics.

The company is also preparing new brand extensions, including recently launched Plosbrio and Poviztra brands in Canada, as part of its competitive strategy against generic alternatives.

Additional information about generic semaglutide developments and pricing comparisons is available through the FAQ section.